We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance

Results: 1-10 of 698

Connecticut and Maine Become the Latest States to Adopt New Drug Pricing Transparency Laws
  • Arent Fox LLP
  • USA
  • June 6 2018

Connecticut and Maine recently joined the increasing number of states to enact drug price transparency laws. Maine’s drug price transparency law (the

The Rising Tide of ADA Litigation Against Health Care Entities
  • Mintz Levin Cohn Ferris Glovsky and Popeo PC
  • USA
  • May 15 2018

Over the past several years, health care entities have increasingly become the target of private and government plaintiffs complaining of disability

No, You Can’t Sleep on the Job, Especially when it’s a Matter of Life or Death!
  • Shawe Rosenthal LLP
  • USA
  • May 11 2018

As an employment attorney, I deal with new issues nearly every day. But, there’s one issue that seems to come up on a regular basis. It involves

Australian Federal Budget 2018-19: Heathcare Overview
  • Baker McKenzie
  • USA
  • May 9 2018

Last night, the Treasurer delivered the Australian Federal Budget for 2018-19. Below is a high level overview of the proposed changes (subject to

Star Ratings and Future Measurement Concepts in the CY 2019 Final Call Letter
  • Sheppard Mullin Richter & Hampton LLP
  • USA
  • April 11 2018

Medicare Part C and Part D Star Ratings are used by CMS to measure the quality of and reflect the experiences of beneficiaries in Medicare Advantage

Global Approvals for Insulin Glargine Promise a More Affordable, Long-Acting Treatment for Diabetes
  • Rothwell, Figg, Ernst & Manbeck, PC
  • USA
  • April 3 2018

Last week, Mylan N.V. and Biocon Ltd. announced that their jointly-developed insulin glargine biosimilar, Semglee, received marketing approval from

Wake-Up Call to Private Equity: Government Names PE as Defendant in a False Claims Act Action
  • Venable LLP
  • USA
  • March 1 2018

In February, the Justice Department unsealed a False Claims Act (FCA) complaint against a compounding pharmacy (the "Complaint"). The Complaint

Medicare Diabetes Prevention Program Enrollment is Now Open
  • K&L Gates
  • USA
  • February 1 2018

As of January 1, 2018, the Centers for Medicare & Medicaid Services (“CMS”) began enrolling suppliers in its new Medicare Diabetes Prevention Program

Mintz Levin Health Care Qui Tam Update
  • Mintz Levin Cohn Ferris Glovsky and Popeo PC
  • USA
  • January 9 2018

We identified 47 health care-related qui tam cases that were unsealed in August and September 2017

CMS Releases CY 2018 Medicare Physician Fee Schedule Final Rule
  • Holland & Knight LLP
  • USA
  • November 10 2017

The Centers for Medicare & Medicaid Services (CMS) on Nov. 2, 2017, posted the Calendar Year (CY) 2018 Medicare Physician Fee Schedule (MPFS) Final